Pacira Pharmaceuticals stock analysis
Pacira Pharmaceuticals (82P) Stock Price & Analysis
82P Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 1.23B
- Enterprise Value
- CHF 1.07B
- Total Cash (Recent Filing)
- CHF 295.58M
- Total Debt (Recent Filing)
- CHF 340.28M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Substantially Improved Balance Sheet
Debt reduction from roughly $1.13B to $340M and a very low reported debt-to-equity level materially improve financial flexibility. This lowers balance-sheet pressure and leaves more capacity to fund commercialization and pipeline work through normal operating cycles.
Strong Cash Generation
Consistent operating cash flow and $169M of TTM free cash flow indicate strong conversion of accounting earnings into internally generated funds. That supports investment in products and studies, strengthens liquidity, and reduces reliance on additional borrowing.
Expanding Payer Access
Broader reimbursement and preferred formulary placement can remove barriers to physician adoption and institutional purchasing. Coverage across roughly 150 million lives strengthens the commercial foundation for EXPAREL and ZILRETTA beyond any single quarter.
Bears Say
Sharp TTM Revenue Contraction
A 38.4% TTM revenue decline signals that recent profitability has not yet been matched by durable top-line momentum. Continued contraction could reduce operating leverage, weaken reinvestment capacity, and make future growth more dependent on new indications or products.
Gross Margin Pressure And Rising Expenses
Lower gross margin combined with higher research and selling costs can compress earnings even when product sales grow. If this pattern persists, Pacira may have less operating leverage to convert commercial progress and pipeline investment into durable bottom-line improvement.
EXPAREL Royalty Dispute Remains Unresolved
The partial reversal creates continuing legal and financial uncertainty around EXPAREL royalties, including the amount of any eventual obligation. A remand could produce additional costs and distract management while reducing confidence in the product's future cash economics.
82P FAQ
What is Pacira Pharmaceuticals’s market cap?
When is Pacira Pharmaceuticals’s upcoming earnings report date?
How were Pacira Pharmaceuticals’s earnings last quarter?
Is Pacira Pharmaceuticals overvalued?
Does Pacira Pharmaceuticals pay dividends?
What is Pacira Pharmaceuticals’s EPS estimate?
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Pacira Pharmaceuticals Stock Smart Score
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Frank D. Lee
- Employees
- 827
- Website
- www.pacira.com
- Address
- 2000 Sierra Point Parkway, Brisbane, CA, 94005, US
Pacira Pharmaceuticals (82P) Earnings & Revenues
82P Company Deck
82P Earnings Call
Earnings Call SentimentPositive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.
View all CH:82P earnings summaries












